Ikena Oncology Inc expected to post a loss of 48 cents a share - Earnings Preview

ImageneBio

13/03/2023 11:24

* Ikena Oncology Inc  IKNA.OQ   IKNA.O  is expected to show
a fall
in quarterly revenue when it reports  results on March 15
(estimated). 
    * The Boston Massachusetts-based  company is expected to
report  a
70.2% decrease in revenue to $6.016 million from $20.22 million
a year ago, according to the mean estimate from 3 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Ikena Oncology Inc
is for
a loss of 48 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Ikena
Oncology
Inc is $22​, above​ its last closing price of $4.51. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.48       -0.50      -0.48     Beat    3.1
 Jun. 30 2022  -0.47       -0.49      -0.57     Missed  -16.8
 Mar. 31 2022  -0.40       -0.42      -0.47     Missed  -12.4​
 Dec. 31 2021  -0.57       -0.51      0.07      Beat    113.7
 ​​Sep.        -0.41       -0.42      -0.40     Beat    4.8
 30 2021                                                
 Jun. 30 2021  -0.35       -0.36      -0.35     Beat    1.8​
 Mar. 31 2021  -0.68       -0.68      -2.52     Missed  -271.3
 This summary was machine generated March 13 at 11:24 GMT.  All
figures in US dollars  unless otherwise stated